704 related articles for article (PubMed ID: 31904487)
21. Role of the transcriptional coactivators YAP/TAZ in liver cancer.
Zhang S; Zhou D
Curr Opin Cell Biol; 2019 Dec; 61():64-71. PubMed ID: 31387016
[TBL] [Abstract][Full Text] [Related]
22. Hippo signaling promotes JNK-dependent cell migration.
Ma X; Wang H; Ji J; Xu W; Sun Y; Li W; Zhang X; Chen J; Xue L
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1934-1939. PubMed ID: 28174264
[TBL] [Abstract][Full Text] [Related]
23. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
Kim M; Kim T; Johnson RL; Lim DS
Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
[TBL] [Abstract][Full Text] [Related]
24. MAML1/2 promote YAP/TAZ nuclear localization and tumorigenesis.
Kim J; Kwon H; Shin YK; Song G; Lee T; Kim Y; Jeong W; Lee U; Zhang X; Nam G; Jeung HC; Kim W; Jho EH
Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13529-13540. PubMed ID: 32482852
[TBL] [Abstract][Full Text] [Related]
25. TAZ and YAP are frequently activated oncoproteins in sarcomas.
Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
[TBL] [Abstract][Full Text] [Related]
26. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
[TBL] [Abstract][Full Text] [Related]
27. USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ.
Zhu H; Yan F; Yuan T; Qian M; Zhou T; Dai X; Cao J; Ying M; Dong X; He Q; Yang B
Cancer Res; 2020 Jun; 80(11):2204-2216. PubMed ID: 32217697
[TBL] [Abstract][Full Text] [Related]
28. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
Zhu J; Wu T; Lin Q
Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
[TBL] [Abstract][Full Text] [Related]
29. YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC.
Choi W; Kim J; Park J; Lee DH; Hwang D; Kim JH; Ashktorab H; Smoot D; Kim SY; Choi C; Koh GY; Lim DS
Cancer Res; 2018 Jun; 78(12):3306-3320. PubMed ID: 29669762
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells.
Zhang T; Zhang J; You X; Liu Q; Du Y; Gao Y; Shan C; Kong G; Wang Y; Yang X; Ye L; Zhang X
Hepatology; 2012 Dec; 56(6):2051-9. PubMed ID: 22707013
[TBL] [Abstract][Full Text] [Related]
31. Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells.
Wang C; Zhu ZM; Liu CL; He XJ; Zhang HY; Dong JH
Mol Med Rep; 2015 Jun; 11(6):4101-8. PubMed ID: 25625370
[TBL] [Abstract][Full Text] [Related]
32. USP1 modulates hepatocellular carcinoma progression via the Hippo/TAZ axis.
Liu D; Li Q; Zang Y; Li X; Li Z; Zhang P; Feng C; Yang P; Cui J; Sun Y; Wei T; Su P; Zhao X; Yang H; Ding Y
Cell Death Dis; 2023 Apr; 14(4):264. PubMed ID: 37041150
[TBL] [Abstract][Full Text] [Related]
33. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma.
Nallet-Staub F; Marsaud V; Li L; Gilbert C; Dodier S; Bataille V; Sudol M; Herlyn M; Mauviel A
J Invest Dermatol; 2014 Jan; 134(1):123-132. PubMed ID: 23897276
[TBL] [Abstract][Full Text] [Related]
34. NUAK2 is a critical YAP target in liver cancer.
Yuan WC; Pepe-Mooney B; Galli GG; Dill MT; Huang HT; Hao M; Wang Y; Liang H; Calogero RA; Camargo FD
Nat Commun; 2018 Nov; 9(1):4834. PubMed ID: 30446657
[TBL] [Abstract][Full Text] [Related]
35. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
Nishina H
Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
[TBL] [Abstract][Full Text] [Related]
36. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma.
Ahn EY; Kim JS; Kim GJ; Park YN
Mol Cancer Res; 2013 Jul; 11(7):748-58. PubMed ID: 23594797
[TBL] [Abstract][Full Text] [Related]
37. The RNF214-TEAD-YAP signaling axis promotes hepatocellular carcinoma progression via TEAD ubiquitylation.
Lin M; Zheng X; Yan J; Huang F; Chen Y; Ding R; Wan J; Zhang L; Wang C; Pan J; Cao X; Fu K; Lou Y; Feng XH; Ji J; Zhao B; Lan F; Shen L; He X; Qiu Y; Jin J
Nat Commun; 2024 Jun; 15(1):4995. PubMed ID: 38862474
[TBL] [Abstract][Full Text] [Related]
38. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma.
Han SX; Bai E; Jin GH; He CC; Guo XJ; Wang LJ; Li M; Ying X; Zhu Q
J Immunol Res; 2014; 2014():261365. PubMed ID: 24860833
[TBL] [Abstract][Full Text] [Related]
39. LncRNA AY promotes hepatocellular carcinoma metastasis by stimulating
Kang CL; Qi B; Cai QQ; Fu LS; Yang Y; Tang C; Zhu P; Chen QW; Pan J; Chen MH; Wu XZ
Theranostics; 2019; 9(15):4421-4436. PubMed ID: 31285770
[No Abstract] [Full Text] [Related]
40. Common and Distinctive Functions of the Hippo Effectors Taz and Yap in Skeletal Muscle Stem Cell Function.
Sun C; De Mello V; Mohamed A; Ortuste Quiroga HP; Garcia-Munoz A; Al Bloshi A; Tremblay AM; von Kriegsheim A; Collie-Duguid E; Vargesson N; Matallanas D; Wackerhage H; Zammit PS
Stem Cells; 2017 Aug; 35(8):1958-1972. PubMed ID: 28589555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
